| Year |
Citation |
Score |
| 2022 |
Schoedel KA, Kolly C, Gardin A, Neelakantham S, Shakeri-Nejad K. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data. Psychopharmacology. 239: 1-13. PMID 34773483 DOI: 10.1007/s00213-021-06011-6 |
0.306 |
|
| 2021 |
Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep. PMID 34480579 DOI: 10.1093/sleep/zsab224 |
0.341 |
|
| 2018 |
Göhler K, Sokolowska M, Schoedel KA, Nemeth R, Kleideiter E, Szeto I, Eerdekens MH. Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study. Journal of Clinical Psychopharmacology. PMID 30531478 DOI: 10.1097/Jcp.0000000000000995 |
0.325 |
|
| 2018 |
Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy & Behavior : E&B. 88: 162-171. PMID 30286443 DOI: 10.1016/J.Yebeh.2018.07.027 |
0.395 |
|
| 2018 |
Schoedel KA, Gillespie M, Levy-Cooperman N, Shram MJ, Rabinovich-Guilatt L. Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets. Clinical Pharmacology in Drug Development. PMID 29723441 DOI: 10.1002/Cpdd.468 |
0.402 |
|
| 2017 |
Setnik B, Schoedel KA, Levy-Cooperman N, Shram M, Pixton GC, Roland CL. Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology. Journal of Opioid Management. 13: 485-523. PMID 29308594 DOI: 10.5055/Jom.2017.0412 |
0.392 |
|
| 2017 |
Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users. Journal of Opioid Management. 13: 449-464. PMID 29308591 DOI: 10.5055/Jom.2017.0421 |
0.408 |
|
| 2017 |
Schoedel KA, Stockis A, Sellers EM. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users. Epilepsy & Behavior : E&B. PMID 29153631 DOI: 10.1016/J.Yebeh.2017.09.008 |
0.413 |
|
| 2017 |
Bond M, Schoedel KA, Rabinovich-Guilatt L, Gasior M, Tracewell W, Malamut R, Ma Y, Webster LR. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. Pain Medicine (Malden, Mass.). PMID 29016880 DOI: 10.1016/J.Drugalcdep.2015.07.537 |
0.363 |
|
| 2017 |
Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. Journal of Clinical Psychopharmacology. PMID 28926353 DOI: 10.1097/Jcp.0000000000000780 |
0.43 |
|
| 2016 |
Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P. (442) Pharmacodynamic data assessing the abuse potential of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration. The Journal of Pain : Official Journal of the American Pain Society. 17: S85. PMID 28162693 DOI: 10.1016/j.jpain.2016.01.419 |
0.347 |
|
| 2016 |
Levy-Cooperman N, Schoedel KA, Reiz JL, Thompson D, Chakaraborty B, Geoffroy P, Michalko KJ. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users. Journal of Opioid Management. 12: 165-80. PMID 27435437 DOI: 10.5055/Jom.2016.0329 |
0.448 |
|
| 2016 |
Levy-Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial. Epilepsy & Behavior : E&B. 61: 63-71. PMID 27315134 DOI: 10.1016/J.Yebeh.2016.05.010 |
0.382 |
|
| 2016 |
Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. Journal of Clinical Psychopharmacology. PMID 27253658 DOI: 10.1097/Jcp.0000000000000516 |
0.468 |
|
| 2016 |
Koblan KS, Hopkins SC, Sarma K, Gallina N, Jin F, Levy-Cooperman N, Schoedel KA, Loebel A. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users Drug and Alcohol Dependence. 159: 26-34. DOI: 10.1016/j.drugalcdep.2015.10.029 |
0.311 |
|
| 2015 |
Shram M, Schoedel K, Chen N, Kelsh D, O’Brien C, Robertson B, Hsu T. An exploratory human abuse potential assessment of centanafadine, a novel triple reuptake inhibitor Drug and Alcohol Dependence. 156: e203-e204. DOI: 10.1016/J.Drugalcdep.2015.07.548 |
0.308 |
|
| 2015 |
Sellers EM, Cruz H, Dingemanse J, Chakraborty B, Schoedel K. Abuse potential of a dual orexin receptor antagonist: A randomized, double-blind, crossover study in recreational drug users Drug and Alcohol Dependence. 146: e93-e94. DOI: 10.1016/J.Drugalcdep.2014.09.622 |
0.424 |
|
| 2015 |
Schoedel K, Levy-Cooperman N, Basseches P, Butterfield K, Hewitt D, Larson P, Troyer M, Sellers EM, de Haes JU. Assessment of human abuse potential of preladenant (a centrally-acting A2A antagonist) compared to phentermine and placebo in recreational stimulant users Drug and Alcohol Dependence. 146: e91. DOI: 10.1016/J.Drugalcdep.2014.09.615 |
0.45 |
|
| 2015 |
Levy-Cooperman N, Schoedel KA, Reiz J, Thompson D, Chakaraborty B, Geoffroy P, Michalko K. Effect of co-administration of naloxone on intravenous hydromorphone abuse potential in non-treatment-seeking, opioid-dependent drug users Drug and Alcohol Dependence. 146: e176-e177. DOI: 10.1016/J.Drugalcdep.2014.09.396 |
0.441 |
|
| 2015 |
Blum D, Levy-Cooperman N, Cheng H, Chakaraborty B, Hopyan T, Faulkner J, Schoedel K. Abuse potential of eslicarbazepine acetate in recreational sedative users Drug and Alcohol Dependence. 146: e224. DOI: 10.1016/J.Drugalcdep.2014.09.077 |
0.341 |
|
| 2015 |
Mansbach RS, Schoedel KA. Incorporation of Abuse Potential Assessment into the Development of New Prescription Drugs Pharmaceutical Medicine. 29: 141-153. DOI: 10.1007/S40290-015-0095-5 |
0.43 |
|
| 2014 |
Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment. 10: 1161-74. PMID 25061302 DOI: 10.2147/Ndt.S30713 |
0.329 |
|
| 2014 |
Romach MK, Schoedel KA, Sellers EM. Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology. 87: 81-90. PMID 24793872 DOI: 10.1016/J.Neuropharm.2014.04.014 |
0.412 |
|
| 2014 |
Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. Cns Drugs. 28: 361-72. PMID 24627301 DOI: 10.1007/S40263-014-0150-X |
0.368 |
|
| 2014 |
Schoedel KA, Setnik B, Roland CL, Pixton G, Shram M, Levy-Cooperman N. Review of human abuse potential study methodology for abuse-deterrent formulations Drug and Alcohol Dependence. 140: e199. DOI: 10.1016/J.Drugalcdep.2014.02.554 |
0.426 |
|
| 2014 |
Levy-Cooperman N, Mills C, Shram M, Schoedel KA. Reducing subject burden: Identifying critical measures in human abuse potential studies using factor analysis Drug and Alcohol Dependence. 140: e121. DOI: 10.1016/J.Drugalcdep.2014.02.346 |
0.32 |
|
| 2014 |
Sellers EM, Shram MJ, Schoedel KA. The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond Pharmaceutical Medicine. 28: 317-327. DOI: 10.1007/S40290-014-0067-1 |
0.374 |
|
| 2013 |
Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. Clinical Pharmacology in Drug Development. 2: 285-94. PMID 27121791 DOI: 10.1002/Cpdd.36 |
0.336 |
|
| 2013 |
Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug and Alcohol Dependence. 130: 13-23. PMID 23415386 DOI: 10.1016/J.Drugalcdep.2012.12.028 |
0.405 |
|
| 2012 |
Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxectaâ„¢) tablets in nondependent recreational opioid users. Journal of Opioid Management. 8: 315-27. PMID 23247908 DOI: 10.5055/Jom.2012.0131 |
0.361 |
|
| 2012 |
Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. Journal of Clinical Psychopharmacology. 32: 492-502. PMID 22722508 DOI: 10.1097/Jcp.0B013E31825D380D |
0.376 |
|
| 2012 |
Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clinical Drug Investigation. 32: e1-15. PMID 22712629 DOI: 10.1007/Bf03261905 |
0.311 |
|
| 2012 |
Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clinical Drug Investigation. 32: 157-69. PMID 22283559 DOI: 10.2165/11599870-000000000-00000 |
0.367 |
|
| 2011 |
Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. Journal of Opioid Management. 7: 179-92. PMID 21823549 DOI: 10.5055/Jom.2011.0061 |
0.308 |
|
| 2011 |
Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacology. 26: 224-36. PMID 21671456 DOI: 10.1002/Hup.1196 |
0.364 |
|
| 2011 |
Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clinical Pharmacology and Therapeutics. 89: 683-92. PMID 21412231 DOI: 10.1038/Clpt.2011.20 |
0.424 |
|
| 2010 |
Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM. The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. Drug and Alcohol Dependence. 112: 173-7. PMID 20817417 DOI: 10.1016/J.Drugalcdep.2010.07.001 |
0.422 |
|
| 2010 |
Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical Pharmacology and Therapeutics. 88: 69-78. PMID 20520602 DOI: 10.1038/Clpt.2010.67 |
0.424 |
|
| 2010 |
Schoedel K, Chen N, Guy G, Wright S, Patel A, White L, Stott C, Russo E, Sellers E. P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users European Neuropsychopharmacology. 20: S587. DOI: 10.1016/S0924-977X(10)70893-2 |
0.36 |
|
| 2008 |
Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing standards and expectations. Clinical Pharmacology and Therapeutics. 83: 622-6. PMID 18212799 DOI: 10.1038/Sj.Clpt.6100492 |
0.431 |
|
| 2008 |
Schoedel K, Romach M, Sellers E. P.6.c.009 Human abuse potential studies: subjective response patterns and clinically relevant effects of abused drugs European Neuropsychopharmacology. 18: S537. DOI: 10.1016/S0924-977X(08)70813-7 |
0.41 |
|
| 2007 |
Wall TL, Schoedel K, Ring HZ, Luczak SE, Katsuyoshi DM, Tyndale RF. Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 9: S459-74. PMID 17978975 DOI: 10.1080/14622200701587045 |
0.495 |
|
| 2007 |
Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. Journal of Clinical Pharmacology. 47: 1476-88. PMID 17962423 DOI: 10.1177/0091270007308615 |
0.383 |
|
| 2007 |
Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. Journal of Clinical Psychopharmacology. 27: 459-67. PMID 17873677 DOI: 10.1097/Jcp.0B013E3181515205 |
0.455 |
|
| 2006 |
SCHOEDEL K, PARASRAMPURIA D, SCHULLER R, SILBER S, SELLERS E. PII-73Pharmacodynamic (PD) modeling of subjective effects in a randomized double blind crossover abuse liability study of OROS® (OROS-MP) and immediate-release methylphenidate (IR-MP) in recreational stimulant users Clinical Pharmacology & Therapeutics. 79: P55-P55. DOI: 10.1016/J.Clpt.2005.12.198 |
0.333 |
|
| 2004 |
Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 14: 615-26. PMID 15475735 DOI: 10.1097/00008571-200409000-00006 |
0.477 |
|
| 2004 |
Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology and Therapeutics. 76: 64-72. PMID 15229465 DOI: 10.1016/J.Clpt.2004.02.011 |
0.529 |
|
| 2003 |
Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochimica Et Biophysica Acta. 1619: 283-90. PMID 12573488 DOI: 10.1016/S0304-4165(02)00487-7 |
0.516 |
|
| 2003 |
Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Molecular Pharmacology. 63: 96-104. PMID 12488541 DOI: 10.1124/Mol.63.1.96 |
0.507 |
|
| 2001 |
Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochemical Pharmacology. 62: 1025-36. PMID 11597571 DOI: 10.1016/S0006-2952(01)00744-4 |
0.49 |
|
| Show low-probability matches. |